Economic burden of diabetes in Telangana: A Cost of illness study

  • Hemanth kumar Annam Anurag Pharmacy College, Ananthagiri, Kodad, Suryapet, Telangana.
  • Priyanka Nomula Anurag Pharmacy College, Ananthagiri, Kodad, Suryapet, Telangana.
  • Harika Gorla Anurag Pharmacy College, Ananthagiri, Kodad, Suryapet, Telangana.


The purpose of this study is to analyze the economic burden on people in Telangana due to diabetes. In Telangana, a prospective observational study was conducted by collecting patient data. 252 patient’s data was gathered in 6 months period. This data includes health care costs and complications that is both microvascular complications (Neuropathy, Retinopathy & Nephropathy) and macrovascular complications (Coronary heart disease, Congestive heart failure, Myocardial infarction & Peripheral artery disease). The collected data consists of direct and indirect costs which was analyzed & calculated average cost spent in the treatment of diabetic patients. All the type 2 diabetes mellitus patients who are on anti – diabetic drugs irrespective of their co- morbidities & gender were included. Patients who are not on regular medication were excluded from the study. In this study , cost of illness of type-2 diabetes mellitus patients with & without complications were compared. The total cost of treatment per annum in patients without complications was USD 374.77 & in patients with complications was USD 497.763.

Keywords: Cost of illness, Economic burden, Type-2 diabetes mellitus, Complications


Download data is not yet available.


1. Kannan, Arshad, Senthil K. A study on drug Utilization of oral hypoglycemic agents in type-2 Diabetic patient S. Asian J pharm clin res. 2011; 5:60-4
2. American Diabetes Association. Classification and diagnosis of diabetes: standards of medical care in diabetes - 2018. Diabetes Care 2018; 41[suppl 1]: S13e27.
3. Mayer-Davis EJ, Lawrence JM, Dabelea D, et al. SEARCH for Diabetes in Youth Study. Incidence trends of type 1 and type 2 diabetes among youths, 2002-2012. N Engl J Med 2017; 376: 1419-29.
4. Sekikawa A, Tominaga M, Takahashi K, Eguchi H, Igarashi M, et al. [1993] Prevalence of diabetes and impaired glucose tolerance in Funagata area, Japan. Diabetes Care 16: 570-574.
5. Ramachandran A, Snehalatha C, Latha E, Vijay V, Viswanathan M [1997] Rising prevalence of NIDDM in an urban population in India. Diabetologia 40: 232-237.
6. Craig ME, Hattersley A, Donaghue KC [2009] Definition, epidemiology and classification of diabetes in children and adolescents. Pediatr Diabetes 10 Suppl 12: 3-12.
7. Chaturvedi N. The burden of diabetes and its complications: Trends and implications for intervention. Diabetes Res Clin Pract. 2007; 76[3]: S3–S12.
8. Jefferson T, Demicheli V, Mugford M. Cost-of-illness studies, elementary economic evaluation in health care. 2nd Ed., London: BMJ Publishing Group, 2000:17-29.
9. Haines, L., Wan, K., Lynn, R., Barrett, T. and Shield, J. [2007] Rising incidence of type 2 diabetes in children in the UK. Diabetes Care 30: 1097–1101.
10. Vigersky RA. An overview of management issues in adult patients with type 2 diabetes mellitus. J Diabetes Sci Technol. 2011; 5[2]: 245–250.
11. Brinsmead R [2003]: Use of Pharmacoeconomics in prescribing research. J Clin PharmTher 28:339-46.
12. Doubilet P, Weinstein MC, McNeil BJ [1986]: Use and misuse of the term “cost effective” in medicine. New Eng J Med, 314[4]:253-6.
13. Drummond MF, Richardson SW [1997]: Users’ Guides to the Medical Literature. How to Use an Article on Economic Analysis of Clinical Practice. 277[19]:1552-7.
63 Views | 46 Downloads
How to Cite
Annam, H. kumar, P. Nomula, and H. Gorla. “Economic Burden of Diabetes in Telangana: A Cost of Illness Study”. World Journal of Current Medical and Pharmaceutical Research, Vol. 2, no. 2, May 2020, pp. 148-51, doi:10.37022/WJCMPR.2020.2211.
Research Articles